Tesamorelin

Tesamorelin API

Ko te Tesamorelin he rongoa peptide waihanga, ko te ingoa katoa ko te ThGRF(1-44)NH₂, he tairitenga o te homoni whakatipu (GHRH). Ka whakaihiihi i te pituitary o mua ki te huna i te homoni tupu (GH) ma te whakatauira i te mahi a te GHRH endogenous, na reira ka piki ake te taumata o te insulin-rite tipu 1 (IGF-1), ka mau mai i te raupapa o nga painga i roto i te whakawhitinga me te hanga kiko.

I tenei wa, kua whakaaetia a Tesamorelin e te FDA mo te maimoatanga o te lipodystrophy e pa ana ki te HIV, ina koa mo te whakaheke i te kohinga ngako visceral abdominal (visceral adipose tissue, VAT). Kua rangahauhia hoki mo ** anti-aging, metabolic syndrome, mate ate ngako-kore-waipiro (NAFLD/NASH)** me etahi atu mara, e whakaatu ana i nga tumanakohanga whanui.
Te tikanga mahi

Ko te Tesamorelin he peptide waikawa 44-amino me te hanganga tino rite ki te GHRH taiao. Ko tana tikanga mahi ko:

Whakahohehia te kaiwhiwhi GHRH (GHRHR) ki te whakaongaonga i te pituitary o mua ki te tuku i te GH.

I muri i te whakanui ake o te GH, ka mahi i runga i te ate me nga kopa a tawhio noa ki te whakanui ake i te hanganga IGF-1.

Ko te GH me te IGF-1 ka uru tahi ki te whakangao ngako, te whakahiato pūmua, te whakatikatika pūtau me te tiaki kiato wheua.

Ko te nuinga o te mahi i runga i te pirau ngako visceral (te whakakorikori ngako) me te iti o te paanga ki te ngako subcutaneous.

Ka whakatauritea ki te werohanga o waho tika o te GH, ka whakatairanga a Tesamorelin i te hunanga o te GH na roto i nga tikanga endogenous, e tata atu ana ki te riipene whaiaroaro me te karo i nga tauhohenga kino na te nui o te GH, penei i te pupuri wai me te aukati insulin.

Te rangahau me te kaha haumanu

Ko te kaha o Tesamorelin kua whakamanahia e nga whakamatautau haumanu maha, ina koa i nga waahanga e whai ake nei:

1. Lipodystrophy e pa ana ki te HIV (Nga tohu kua whakaaetia e te FDA)

Ka taea e Tesamorelin te whakaheke i te VAT puku (he hekenga toharite o 15-20%);

Whakanuia nga taumata IGF-1 me te whakapai ake i te ahua o te tinana;

Te whakapai ake i te ahua o te tinana me te whakaiti i te taumahatanga hinengaro e pa ana ki te tohatoha ngako;

Kaore e tino pa ki te paparanga ngako subcutaneous, kiato wheua, papatipu uaua ranei.

2. Steatohepatitis kore-waipiro (NASH) me te fibrosis ate

Kua whakaatuhia e nga whakamatautau haumanu ka taea e Tesamorelin te whakaiti i te ihirangi ngako ate (MRI-PDFF imaging);

Ko te tumanako ka pai ake te aro o te insulin hepatocyte;

He tino whai hua mo te hunga mate HIV me te NAFLD, a ka whai waahi te whakamarumaru o te tuuroro whanui.

3. Metabolic syndrome and insulin resistance

Ka tino whakaitihia e Tesamorelin nga taumata triglyceride me te nui o te kopu;

Te whakapai ake i te taurangi HOMA-IR me te awhina ki te whakapai ake i te aukati insulin;

Kua whakaatuhia e nga rangahau ka taea e ia te whakarei ake i te kaha o te whakahiato pūmua uaua, e whai hua ana ki te hunga kaumātua, ki te whakaora mai i nga mate mau tonu.

Te hanga API me te mana kounga

Ko te Tesamorelin API e whakaratohia ana e to tatou Roopu Gentolex e whakamahi ana i te hangarau whakahiato peptide synthesis (SPPS) o te wahanga totoka, ka hangaia i raro i te taiao GMP. Kei a ia nga ahuatanga e whai ake nei:

Pure ≥99% (HPLC)
Karekau he endotoxin, he konganuku taumaha, he tohu whakarewanga toenga
Te raupapa waikawa amino me te whakapumautanga o te hanganga na LC-MS/NMR
Whakaratohia te taumata karamu ki te taumata kirokaramu kua whakaritea